Cargando…
Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth
We previously identified CLEC14A as a tumour endothelial marker. Here we show CLEC14A is a regulator of sprouting angiogenesis in vitro and in vivo. Using a HUVEC spheroid sprouting assay we found CLEC14A to be a regulator of sprout initiation. Analysis of endothelial sprouting in aortic ring and in...
Autores principales: | PJ, Noy, P, Lodhia, K, Khan, X, Zhuang, DG, Ward, AR, Verissimo, A, Bacon, R, Bicknell |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724939/ https://www.ncbi.nlm.nih.gov/pubmed/25745997 http://dx.doi.org/10.1038/onc.2015.34 |
Ejemplares similares
-
An evaluation of the tumour endothelial marker CLEC14A as a therapeutic target in solid tumours
por: Robinson, Joseph, et al.
Publicado: (2020) -
Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface
por: Khan, K A, et al.
Publicado: (2017) -
Tumour vascularization: sprouting angiogenesis and beyond
por: Hillen, Femke, et al.
Publicado: (2007) -
Inhibition of VEGF‐dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a
por: Kim, Taek‐Keun, et al.
Publicado: (2018) -
Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization
por: Li, Yang, et al.
Publicado: (2023)